S&P 500   4,270.96 (-0.07%)
DOW   33,876.15 (-0.31%)
QQQ   329.08 (+0.18%)
AAPL   173.96 (-0.34%)
MSFT   290.48 (-0.29%)
META   174.49 (-0.21%)
GOOGL   119.90 (+0.29%)
AMZN   142.02 (-0.06%)
TSLA   911.03 (-0.11%)
NVDA   186.78 (+1.87%)
NIO   19.83 (-1.25%)
BABA   90.38 (+0.68%)
AMD   100.33 (+2.10%)
MU   62.81 (+1.93%)
T   18.42 (+0.00%)
CGC   3.79 (-6.65%)
F   16.00 (-0.19%)
GE   79.14 (-0.98%)
DIS   122.13 (-0.55%)
AMC   20.04 (-6.18%)
PYPL   98.55 (-0.88%)
PFE   48.56 (-1.44%)
NFLX   245.03 (+1.61%)
S&P 500   4,270.96 (-0.07%)
DOW   33,876.15 (-0.31%)
QQQ   329.08 (+0.18%)
AAPL   173.96 (-0.34%)
MSFT   290.48 (-0.29%)
META   174.49 (-0.21%)
GOOGL   119.90 (+0.29%)
AMZN   142.02 (-0.06%)
TSLA   911.03 (-0.11%)
NVDA   186.78 (+1.87%)
NIO   19.83 (-1.25%)
BABA   90.38 (+0.68%)
AMD   100.33 (+2.10%)
MU   62.81 (+1.93%)
T   18.42 (+0.00%)
CGC   3.79 (-6.65%)
F   16.00 (-0.19%)
GE   79.14 (-0.98%)
DIS   122.13 (-0.55%)
AMC   20.04 (-6.18%)
PYPL   98.55 (-0.88%)
PFE   48.56 (-1.44%)
NFLX   245.03 (+1.61%)
S&P 500   4,270.96 (-0.07%)
DOW   33,876.15 (-0.31%)
QQQ   329.08 (+0.18%)
AAPL   173.96 (-0.34%)
MSFT   290.48 (-0.29%)
META   174.49 (-0.21%)
GOOGL   119.90 (+0.29%)
AMZN   142.02 (-0.06%)
TSLA   911.03 (-0.11%)
NVDA   186.78 (+1.87%)
NIO   19.83 (-1.25%)
BABA   90.38 (+0.68%)
AMD   100.33 (+2.10%)
MU   62.81 (+1.93%)
T   18.42 (+0.00%)
CGC   3.79 (-6.65%)
F   16.00 (-0.19%)
GE   79.14 (-0.98%)
DIS   122.13 (-0.55%)
AMC   20.04 (-6.18%)
PYPL   98.55 (-0.88%)
PFE   48.56 (-1.44%)
NFLX   245.03 (+1.61%)
S&P 500   4,270.96 (-0.07%)
DOW   33,876.15 (-0.31%)
QQQ   329.08 (+0.18%)
AAPL   173.96 (-0.34%)
MSFT   290.48 (-0.29%)
META   174.49 (-0.21%)
GOOGL   119.90 (+0.29%)
AMZN   142.02 (-0.06%)
TSLA   911.03 (-0.11%)
NVDA   186.78 (+1.87%)
NIO   19.83 (-1.25%)
BABA   90.38 (+0.68%)
AMD   100.33 (+2.10%)
MU   62.81 (+1.93%)
T   18.42 (+0.00%)
CGC   3.79 (-6.65%)
F   16.00 (-0.19%)
GE   79.14 (-0.98%)
DIS   122.13 (-0.55%)
AMC   20.04 (-6.18%)
PYPL   98.55 (-0.88%)
PFE   48.56 (-1.44%)
NFLX   245.03 (+1.61%)
NASDAQ:INCY

Incyte - INCY Stock Forecast, Price & News

$73.56
-0.30 (-0.41%)
(As of 08/18/2022 12:40 PM ET)
Add
Compare
Today's Range
$72.41
$74.05
50-Day Range
$66.18
$82.86
52-Week Range
$61.91
$84.86
Volume
21,300 shs
Average Volume
1.39 million shs
Market Capitalization
$16.36 billion
P/E Ratio
17.31
Dividend Yield
N/A
Price Target
$84.92

Incyte MarketRank™ Forecast

Analyst Rating
Hold
2.30 Rating Score
Upside/​Downside
16.6% Upside
$84.92 Price Target
Short Interest
Healthy
2.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
0.34mentions of Incyte in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$589,387 Sold Last Quarter
Proj. Earnings Growth
40.65%
From $2.46 to $3.46 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.99 out of 5 stars

Medical Sector

30th out of 1,122 stocks

Commercial Physical Research Industry

1st out of 17 stocks

INCY stock logo

About Incyte (NASDAQ:INCY) Stock

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Stock Down 1.5 %

INCY traded down $1.10 during midday trading on Wednesday, hitting $73.86. 797,563 shares of the company's stock traded hands, compared to its average volume of 1,580,862. The company has a market cap of $16.43 billion, a PE ratio of 17.38, a price-to-earnings-growth ratio of 1.22 and a beta of 0.64. The stock's fifty day simple moving average is $76.05 and its 200-day simple moving average is $75.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.91 and a quick ratio of 3.85. Incyte has a one year low of $61.91 and a one year high of $84.86.

Incyte (NASDAQ:INCY - Get Rating) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.79 by $0.22. Incyte had a return on equity of 13.02% and a net margin of 28.46%. The company had revenue of $911.40 million for the quarter, compared to the consensus estimate of $818.25 million. During the same quarter last year, the company posted $0.65 earnings per share. The company's revenue for the quarter was up 29.1% compared to the same quarter last year. As a group, equities analysts anticipate that Incyte will post 2.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

INCY has been the subject of several research analyst reports. Guggenheim cut Incyte to a "neutral" rating in a research note on Tuesday, August 9th. Stifel Nicolaus boosted their price target on Incyte from $75.00 to $77.00 in a research report on Tuesday, May 3rd. TheStreet upgraded shares of Incyte from a "c" rating to a "b" rating in a research report on Tuesday, August 2nd. StockNews.com lowered shares of Incyte from a "strong-buy" rating to a "buy" rating in a research note on Thursday, August 11th. Finally, Evercore ISI downgraded shares of Incyte from an "outperform" rating to an "inline" rating and reduced their price objective for the stock from $90.00 to $78.00 in a research report on Wednesday, August 3rd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $84.92.

Insider Buying and Selling at Incyte

In other Incyte news, EVP Vijay K. Iyengar sold 5,787 shares of the stock in a transaction that occurred on Thursday, July 7th. The stock was sold at an average price of $79.38, for a total transaction of $459,372.06. Following the transaction, the executive vice president now owns 40,313 shares in the company, valued at $3,200,045.94. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Incyte news, insider Thomas Tray sold 1,564 shares of Incyte stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $83.13, for a total transaction of $130,015.32. Following the sale, the insider now owns 17,702 shares in the company, valued at $1,471,567.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Vijay K. Iyengar sold 5,787 shares of Incyte stock in a transaction dated Thursday, July 7th. The shares were sold at an average price of $79.38, for a total transaction of $459,372.06. Following the transaction, the executive vice president now directly owns 40,313 shares of the company's stock, valued at $3,200,045.94. The disclosure for this sale can be found here. Corporate insiders own 17.50% of the company's stock.

Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Stock News Headlines

Incyte Co. (NASDAQ:INCY) Short Interest Down 12.8% in July
Incyte (NASDAQ:INCY) Stock Rating Lowered by StockNews.com
Incyte (NASDAQ:INCY) Lowered to Neutral at Guggenheim
Evercore ISI Downgrades Incyte (NASDAQ:INCY) to Inline
Incyte (NASDAQ:INCY) Price Target Cut to $98.00
Incyte (NASDAQ:INCY) Upgraded by StockNews.com to Strong-Buy
Guggenheim Downgrades Incyte (NASDAQ:INCY) to Neutral
Form 8-K INCYTE CORP For: Aug 02 - StreetInsider.com
See More Headlines
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Company Calendar

Last Earnings
8/02/2022
Today
8/18/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,094
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$84.92
High Stock Price Forecast
$108.00
Low Stock Price Forecast
$63.00
Forecasted Upside/Downside
+15.4%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$948.58 million
Pretax Margin
18.95%

Debt

Sales & Book Value

Annual Sales
$2.99 billion
Cash Flow
$2.33 per share
Book Value
$18.37 per share

Miscellaneous

Free Float
183,506,000
Market Cap
$16.36 billion
Optionable
Optionable
Beta
0.64

Social Links















INCY Stock - Frequently Asked Questions

Should I buy or sell Incyte stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings
or view top-rated stocks.

What is Incyte's stock price forecast for 2022?

10 analysts have issued 12-month price targets for Incyte's shares. Their INCY share price forecasts range from $63.00 to $108.00. On average, they predict the company's share price to reach $84.92 in the next twelve months. This suggests a possible upside of 15.0% from the stock's current price.
View analysts price targets for INCY
or view top-rated stocks among Wall Street analysts.

How have INCY shares performed in 2022?

Incyte's stock was trading at $73.40 at the beginning of the year. Since then, INCY stock has increased by 0.6% and is now trading at $73.86.
View the best growth stocks for 2022 here
.

When is Incyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our INCY earnings forecast
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) posted its quarterly earnings results on Tuesday, August, 2nd. The biopharmaceutical company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.22. The biopharmaceutical company had revenue of $911.40 million for the quarter, compared to analysts' expectations of $818.25 million. Incyte had a trailing twelve-month return on equity of 13.02% and a net margin of 28.46%. The company's revenue was up 29.1% on a year-over-year basis. During the same period last year, the company earned $0.65 EPS.
Read the conference call transcript
.

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by many different institutional and retail investors. Top institutional shareholders include Dodge & Cox (9.02%), State Street Corp (4.25%), Renaissance Technologies LLC (2.31%), Price T Rowe Associates Inc. MD (1.53%), UBS Asset Management Americas Inc. (0.98%) and Northern Trust Corp (0.90%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends
.

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $73.86.

How much money does Incyte make?

Incyte (NASDAQ:INCY) has a market capitalization of $16.43 billion and generates $2.99 billion in revenue each year. The biopharmaceutical company earns $948.58 million in net income (profit) each year or $4.25 on an earnings per share basis.

How many employees does Incyte have?

The company employs 2,094 workers across the globe.

When was Incyte founded?

Incyte was founded in 1991.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.

This page (NASDAQ:INCY) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.